Weight Loss in Adults Using Semaglutide (Real-world Study)

Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study

The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Inclusion Criteria:

• Initiation of semaglutide for weight management during the study period.
• Age more than or equal to (≥) 18 at treatment initiation
• Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m^2.
• Other inclusion criteria as defined in the protocol are applicable.

Exclusion Criteria:

• Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
• Bariatric surgery at baseline.
• Diabetes at baseline.
• Pregnancy at baseline.